锆-89标记曲妥珠单抗PET/CT检测人表皮生长因子受体2阴性原发乳腺癌患者的人表皮生长因子受体2阳性转移灶
本研究为前瞻性临床试验的第二组,纳入11例确诊人表皮生长因子受体2(HER2)阴性原发乳腺癌且已知转移的患者,行锆-89标记曲妥珠单抗PET/CT筛查可疑HER2阳性转移灶并对阳性病灶活检。4例出现可疑摄取,其中1例活检证实HER2阳性转移,另3例为假阳性。结合先前9例,共20例中3例(15%)病理证实HER2阳性远处转移,6例(30%)为假阳性。
要点
- 锆-89标记曲妥珠单抗PET/CT可在部分HER2阴性原发乳腺癌患者中检出未疑及的HER2阳性转移。
- 第二组11例中4例出现可疑摄取,仅1例活检证实HER2阳性转移。
- 合并20例分析,3例(15%)病理证实HER2阳性远处转移,6例(30%)为假阳性。
核心结论
- 第二组患者证实了锆-89标记曲妥珠单抗PET/CT可在部分HER2阴性原发乳腺癌患者中检出未疑及的HER2阳性转移的概念验证。
- 锆-89标记曲妥珠单抗可疑摄取灶的假阳性问题对该示踪剂的使用构成挑战。
研究设计与样本
- 机构审查委员会批准的前瞻性临床试验(ClinicalTrials.gov标识NCT02286843)中的第二组,纳入11例HER2阴性原发乳腺癌且已知转移的患者。
- 患者行锆-89标记曲妥珠单抗PET/CT筛查提示未疑及HER2阳性转移的锆-89标记曲妥珠单抗摄取灶,并对摄取灶活检行病理HER2状态检测。
主要发现
- 11例均确诊HER2阴性原发乳腺癌,其中4例锆-89标记曲妥珠单抗PET/CT显示可疑病灶。
- 4例中1例活检证实HER2阳性转移,另3例活检显示转移灶为HER2阴性,被视为锆-89标记曲妥珠单抗PET假阳性灶。
- 结合先前9例的已发表报告,共20例HER2阴性原发乳腺癌患者中3例(15%)病理证实HER2阳性远处转移,6例(30%)有可疑锆-89标记曲妥珠单抗摄取灶但病理HER2阴性,被视为假阳性。
局限性
- 原文指出锆-89标记曲妥珠单抗可疑摄取灶的假阳性问题对该示踪剂的使用构成挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to determine if imaging with Zr-trastuzumab, a human epidermal growth factor receptor 2 (HER2)-targeting PET tracer, can detect HER2-positive metastases in patients with HER2-negative primary breast cancer. METHODS: As part of an institutional review board-approved, prospective clinical trial of Zr-trastuzumab PET/CT (ClinicalTrials.gov identifier NCT02286843), a second group of 11 patients with HER2-negative primary breast cancer and known metastatic disease were recruited. Patients with confirmed HER2-negative primary breast cancer underwent Zr-trastuzumab PET/CT to screen for Zr-trastuzumab-avid lesions suggestive of unsuspected HER2-positive metastases. Zr-trastuzumab-avid lesions on PET/CT were biopsied and pathologically examined to determine HER2 status. RESULTS: All 11 patients had confirmed HER2-negative primary breast cancer. Four patients demonstrated suspicious foci on Zr-trastuzumab PET/CT. Of these 4 patients, 1 patient had biopsy-proven HER2-positive metastases. The other 3 patients with suspicious Zr-trastuzumab-avid foci had biopsy demonstrating a metastasis that was HER2-negative and were considered false-positive Zr-trastuzumab PET foci. Combined with a published report of the first 9 patients, there have been a total of 20 HER2-negative primary breast cancer patients, with 3 patients (15%) having pathologically confirmed HER2-positive distant metastases and 6 (30%) with suspicious Zr-trastuzumab-avid foci that were HER2-negative on pathology, which were thus considered false-positive Zr-trastuzumab findings. CONCLUSIONS: This second group of patients confirms the proof of concept that Zr-trastuzumab PET/CT detects unsuspected HER2-positive metastases in a subset of patients with HER2-negtive primary breast cancer. False-positive Zr-trastuzumab-avid foci present a challenge to using this tracer.
引用
- Ulaner GA, Hyman DM, Lyashchenko SK, et al. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. Clin Nucl Med. 2017. PMID: 28872549. doi:10.1097/RLU.0000000000001820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。